Glass Pharms News
On Your Farm BBC R4
Profile of Glass Pharms on BBC R4 Click to Listen Charlotte Smith visits a glass house where a tomato grower (Richard Lewis, MD) and a chemist (James Duckenfield, CEO) have combined their expertise to set up a state-of-the-art nursery producing medicinal cannabis. James Duckenfield and Richard Lewis saw an opening in the market for high tech, high quality production of the crop, which is grown under licence, with the process closely regulated by the Home Office.At a secret location in the English countryside, cannabis plants are cultivated and harvested every day. The facility produces flowers for pharmaceutical use and cost £26...
Coverage on BBC Radio 4
Richard Lewis (MD), James Duckenfield (CEO) on BBC Radio 4Our thanks to BBC Radio 4 for their keen interest in our innovative farming techniques and medical cannabis in the UK. Snipit today and full coverage this Sunday.
Westminster Debate
Our thanks go to Jim Shannon MP for leading a debate in Westminster Hall on medical cannabis attended by two representatives from Glass Pharms. We heard powerful stories of success where medical cannabis has changed people’s lives and associated distress caused to patients from the financial burden and prejudice from poorly briefed police forces. Minister of State for Health, Karin Smyth MP responded with a prepared statement on behalf of the government. The government response focused on the need for more research rather than on improving availability for medicines with well understood safety. View the debate here: https://parliamentlive.tv/event/index/acaa5a0c-1e98-4557-b8a2-925aab7c9a02?in=13:30:00 We have...
CBPMs could save NHS £4B
Allowing CBPMs to be prescribed on the NHS for chronic pain could save the NHS almost £4B per annum, according to a study by York University, part-funded by Glass Pharms. We hope that NICE will review their study from 2019 which used assumptions of medicine cost which are not consistent with the current market.James Duckenfield, CEO of Glass Pharms, “Despite medicinal cannabis being legalised in 2018, there are still only a few NHS patients receiving unlicensed cannabis-derived medicines. We hope that NICE will review the evidence from this Health Economic Analysis and adapt its guidance accordingly. Now is the time...
Releaf + Glass Pharms
Releaf + Glass Pharms agree landmark dealReleaf and Glass Pharms have agreed on a landmark multi-million pound deal that will see it grow 145kg of cannabis flower per month to supply CBPMs for Releaf's patients.Glass Pharms' continuous manufacturing facility will support the rapid growth of Releaf's clinic, believed to be the fastest growing in the UK.